This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Dry Powder Inhaler Market

Market Insights on Dry Powder Inhaler covering sales outlook, demand forecast & up-to-date key trends

Dry Powder Inhaler Market by Product - (Single Dose Dry Powder Inhalers and Multi Dose Dry Powder Inhalers), by Indication- (Asthma, Chronic Obstructive Pulmonary Disease (COPD) & Region for 2021-2031

Dry Powder Inhaler Market Snapshot

[371 Pages Report] Global Dry Powder Inhaler Market is set to experience a significant growth of 4.6% CAGR from 2021 to 2031, with an estimated market value of around US$ 18.9 Bn as of 2021. As per Future Market Insights’ projections, Manually Operated Inhaler Devices hold a substantial share of over 70.9% in 2021 within the global dry powder inhaler market.

Market Outlook:

Data Points

Market Insights

Market Value 2020

US$ 18.1 Bn

Market Value 2021

US$ 18.9 Bn

Market Value 2031

US$ 29.6 Bn

CAGR 2021-2031

4.6%

Market Share of Top 5 Countries

60.5%

Key Market Players

GlaxoSmithKline Plc, AstraZeneca Plc, Novartis AG, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A., Elpen S.A., Vectura Group Plc, Beximco Pharmaceuticals Ltd., Hovione, AptarGroup, Inc., Iconovo AB (Stevanato Group), Sava Healthcare Ltd., MannKind Corporation, Mylan N.V(a part of Viatris) and Pharmaxis

With the utilization of dry powder inhalers in the treatment of a diverse range of diseases, the development of technologically innovative products is surfacing. These “smart technologies” are set to satisfy specific market requirements for the development of cost-effective drug products.

The deep penetration of digital systems into the inhaler market has been advantageous in terms of ruling out several device and design errors. The implementation of microprocessors in inhalers for supporting patients with device usage and handling is positively impacting compliance and product satisfaction.

The development of next-generation inhalers with the integration of smart technologies is likely to drive the growth of the dry powder inhaler market. The integration is set to establish a breakthrough in drug delivery with the primary basis being a tailored performance based on the patient’s/user’s variable breathing patterns.

Technologically advanced dry powder inhalers with digitally enabled platforms along with a friendly user interface will help in preventing or compensating actuation errors that, in turn, will enhance compliance. The growth of digitally operated inhalers devices is also supported by the recent upsurge in digitalization in the healthcare and industrial sectors. This factor will drive the dry powder inhaler market.

The dry powder inhalers are a preferred method of treatment of respiratory ailments over pressurized metered dose inhalers and nebulizers owing to the rising concerns related to the environmental impact of inhaler devices which utilize chloroflouro carbons as propellants.

Thus, the production and design of dry powder inhalers is set to witness a growth over the forecast period, and is expected to offer product manufacturers or key players in the dry powder inhaler market with an optimistic growth opportunity.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

4.56%

H1, 2022 Projected

4.57%

H1, 2022 Outlook

4.17%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 40 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 39 ↓

The global dry powder inhaler market is subject to regulatory changes and device compliance guidelines as per the macroeconomic and industry standards. Comparative analysis of H1-2022 and H1-2021 revealed insights on the market dynamics role on the global market growth.

H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 40 BPS. However, In H1-2022, the market growth rate of dry powder inhalers is expected to fall by 39 basis point share (BPS), as per FMI analysis.

The value change in BPS presents a decline owed to the low adoption rate of dry powder inhalers because of their higher unit cost when compared with standard metered dose inhalers. Moreover, some modalities of dry powder inhalers present issues with drug device interaction, as well as differential patient outcomes owed to the variability in breath actuation as per individual capability.

However, owed to the sustainable development of medical devices, dry powder inhalers propose a reduced emission of aerosols which are harmful to the environment. With a reduced carbon footprint, the market is set to witness an increased uptake over the forecasted years.

Sales Analysis Of Dry Powder Inhalers From 2016 To 2020 Vs Market Outlook For 2021 To 2031

The dry powder inhaler market holds nearly 47.4% of the overall US$ 38.2 Bn respiratory inhalers market in 2020.

The rising global incidence of respiratory disorders such as chronic obstructive pulmonary disease, asthma and even cystic fibrosis has established a worldwide need of dry powder inhalers. Moreover, the increasing air pollution levels, particularly in developing and emerging regions, combined with a surge in the healthcare per capita spending have further bolstered the demand and consumption of dry powder inhaler market over the globe.

Dry powder inhaler devices are commonly utilized to deliver medications into the lungs, such as inhaled corticosteroids. These inhaler devices are breath actuated and the drug is released into the airway only after a deep and fast breath inhalation into the lungs.

Conventional inhalers deliver a puff of medicine whereas, the dry powdered formulation delivered by dry powder inhaler devices delivers a select dose of drug into the lungs, following which the DE agglomeration of drug takes place for quicker effect into the patient’s lungs.

One of the major advantages of dry powder inhalers is that they are also applicable for use in a varied range of diseases. These devices take into account the patient-device interaction, which is a complex process and is highly dependent upon the patient aspiration rate as well as the force of inhalation.

Dry Powder Inhaler Market Download Report Brochure

Moreover, there has been observed, an increasing focus of development in high dose drug delivery, systemic delivery as well as vaccinations via the pulmonary pathway. Hence, the development of specifically designed dry powder inhalers, tailored for patient’s indication as well as the type and units of doses they may require is expected to be a preferred form of drug delivery over the forecast period with cost effective and safe applications.

The market is expected to expand at a considerable growth rate over the next ten years at a CAGR of close to 4.6%, and offer an absolute $ opportunity of US$ 861.0 Mn from 2021 to 2022.

What Are The Key Opportunities For Dry Powder Inhalers Manufacturers?

Confounding problems are existent in clinical trials for dry powder inhalers, specifically, where the possibility of errors by patients with respect to inhaler handling can be high. Distinguishing handling errors by patients from existing clinical effects is complex, particularly in phase III trials where support to patients cannot be contracted.

The impact of digital systems thus presents an opportunity to assist with monitoring and control over all phases of clinical studies. Digital technology can improve clinical outcomes by improving adherence and reducing patient errors through mobile applications connected to the device, which will deliver useful tools including reminders and step-based guidance for the appropriate technique of usage.

On the other hand, medical providers can track patient compliance to the therapeutic regimen in real time. Additionally, the monitoring of symptoms and their worsening is registered along with the compliance tracker and it assists with the prevention of severe disease exacerbations, thus leading to a satisfying patient outcome.

The development of inhalation products poses the possibility of significant errors for drug-device combinations related to the usage of the device by patients, variations in the delivery of drugs, as well as flawed data collection.

These errors may deliver distorted information regarding the therapeutic efficacy of drug formulations and device-based effects in clinical trials. The introduction of programmed tools for use in clinical trials will contribute to an improved understanding of drug-device combinations and their efficiency.

These tools may assist with enhanced data collection processes without being influenced by poor patient compliance as well as administration issues. These automated tools can include incorporated audio-based technologies and devices for monitoring medication compliance.

Connected wearable devices can be beneficial in tracking patient activity and thus evaluating the effect on clinical efficacy with integrated companion applications to capture patient-reported outcomes.

Thus, the change in the landscape of clinical trials is set to be positively impacted by the monitoring of data all through the product life cycle along with patient-reported data in real-time conditions, thus presenting an opportunistic growth for the dry powder inhaler market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What Are The Factors Restraining Demand For Dry Powder Inhalers?

Technological advancements are progressively growing in terms of increasing novel and innovative, integrated, alternative good manufacturing practice-ready approaches, which are associated with next-generation analytical and modelling skills. However, regulations encompassing such progressions are yet to catch up with the developing complex clinical requirements.

This trend is intensified by the acceleration of complexity and the cost of approval for the formulation of orally inhaled and nasal drug products and by the scientific disparity that still exists, particularly for locally acting dry powder inhaler products. 

Considering this, despite existing development, animal models are not applicable to humans and perceptive methods for assessing clinical efficiency along with in-vitro and in-vivo association for inhaled medicines are still inadequate.

In this concern, the outcome of the clinical approach is intensely predisposed by the ambiguous correlation between efficiency and selected clinical endpoints. This risk is greater for therapies in which the pattern of deposition of the drug is directly associated with efficiency.

In spite of thorough assessments and a focus on advances in device design as well as formulation, the impact on the patient in terms of their adherence to therapy, inspiration rate, and correct use of the inhaler are yet to be quantified. This poses a restrictive impact on the growth of the dry powder inhaler market, given the wide-ranging factors associated with the intensity of the impact of disease on the patient, affecting their inspiration rate.

Country-Wise Insights

What Makes the U.S. the Largest Market for Dry Powder Inhalers?

The U.S. dominates the North American region with a total market share of about 90.5% in 2020, and is projected to continue experiencing high growth throughout the forecast period. U.S. is the most lucrative market for dry powder inhalers owing to the combination of a robust healthcare infrastructure accompanied with technologically advanced procedure, an increasing number of patients with respiratory disorders, strictly enforced guidelines by regulatory authorities pertaining to medical devices attributed with respiratory disorder therapeutics, and comparatively high government healthcare spending.

Furthermore, due to the increased prevalence of asthma and other respiratory disorders, as well as the growing geriatric population, the dry powder inhaler market in the United States is expected to develop significantly over the next decade.

Why is U.K. Considered a Lucrative Market for Dry Powder Inhalers in Europe?

U.K. is set to exhibit a CAGR of nearly 4.9% in the European dry powder inhaler market during the forecast period. The rising research and development activities to generate a sustainable base of drug delivery devices in the country as well as an established healthcare infrastructure are some of the factors aiding the growth of dry powder inhalers in the country.

What Makes China an Emerging Market for Dry Powder Inhalers?

China holds 38.9% share in the East Asia dry powder inhaler market in 2020, and is projected to increase at a CAGR rate of 5.4% during the forecast period. This growth is associated with the rising deployment of automated systems and devices into an integrated platform for patient monitoring as well as drug delivery devices, rising healthcare costs and rapidly improving medical infrastructure. All these factors are expected to drive market growth in the coming years in China.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-Wise Insights

Which Dry Powder Inhalers Product is Driving Market Growth?

Multi Dose dry powder inhalers project a lucrative growth at a CAGR of 4.6% till the end of the forecast period, with a market share of over 56.5% in 2020 owing to increasing demand and utilization worldwide. These inhalers dispense a multiple unit of dosage for a specified indication of the patient, ensuring quick deposition into the lungs, for improved patient outcome and are convenient and easy to use.

Which Indication is Largely of Focus in the Dry powder inhaler market?

Asthma holds a revenue share of 44.7% in 2020 in the global dry powder inhaler market and are projected to hold a share over the forecast period with the estimation being 42.8%. The global burden of respiratory diseases is quite large, and asthma is one of the most common respiratory diseases among the global population, owing to the rise in infectious diseases and the rising air pollution in the emerging economies.

Which Function Holds a Dominant Stance in the Global Dry powder inhaler market?

Manually operated inhaler devices holds a revenue share of 71.0% in 2020 and are projected to hold a share over the forecast period with the estimation being 71.4%. Since the dry powder inhalers are breath actuated, the device ensures the delivery of drugs in a much efficient manner, depending upon the patient’s aspiration rate and the force of inhalation.

Which End User Benefits The Most by Employment of Dry Powder Inhalers?

Institutional Sales lead the dry powder inhaler market with more than 48% market share in 2020. Most device prescriptions are made after careful assessment of the patient’s condition. Dry powder inhalers experience growing institutional sales owing to the physician based assessment and patient compliance.

What is the Impact of COVID-19 on the Dry Powder Inhalers Industry?

The epidemic has had a tremendous influence on various businesses around the world. This impact has shook the economy and pushed the system off balance.

Many people have died as a result of the spread of coronavirus over the world. This epidemic has resulted in a slew of breathing problems and lung disorders, which have been incredibly dangerous for persons who already have asthma, and is predicted to drive up demand for dry powder inhalers.

Breathlessness or shortness of breath is also a prevalent symptom among COVID-19 patients. This was expected to contribute to an increase in dry powder inhaler sales during epidemic.

Several key players extended their focus onto the development of novel and alternate drug delivery methods, with improved animal models to reduce cost and ensure successful clinical benefits.

However, during the recovery period, the dry powder inhaler market is expected to witness a boost in terms of sales, owing to the advancements in the device design and engineering, as well as its efficacy in the delivery of drugs through the pulmonary pathway.

Competitive Landscape

Leading players in the dry powder inhaler market are focusing their efforts on producing next generation products and adopting patient centric approaches in the development of innovative dry powder inhaler devices to maximise penetration of the product and its utilization across the globe.

Additionally, the market participants are investing money into new device architectures, powder formulations, and particle engineering research and development and are likely to continue to focus on improving particle qualities and developing efficient inhaler designs.

For instance:

  • In September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced that the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta  for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.
  • In August 2021, Pharmaxis granted Aptar Pharma, an exclusive option to develop and promote high payload dry powder inhalers.

Similarly, recent developments related to companies manufacturing dry powder inhalers products have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope As Per Dry Powder Inhalers Industry Analysis

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa

Key Countries Covered

US, Canada,  Brazil,  Mexico, Argentina, Germany, U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, and South Africa

Key Market Segments Covered

Product, Indication, Function, End User and Region

Key Companies Profiled

  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • Chiesi Farmaceutici S.p.A.
  • Elpen S.A.
  • Vectura Group Plc
  • Beximco Pharmaceuticals Ltd.
  • Hovione
  • AptarGroup, Inc.
  • Iconovo AB (Stevanato Group)
  • Sava Healthcare Ltd.
  • MannKind Corporation
  • Mylan N.V(a part of Viatris)
  • Pharmaxis

Pricing

Available upon Request

Key Market Segments Covered In Dry Powder Inhalers Industry Research

By Product :

  • Single Dose Dry Powder Inhalers
  • Multi Dose Dry Powder Inhalers

By Indication :

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Arterial Hypertension
  • Diabetes
  • Cystic Fibrosis

By Function :

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

By End User :

  • Institutional Sales
    • Hospital Pharmacies
    • Cancer Research
    • Office based Speciality Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
  • Mail Order Pharmacies

By Region :

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global dry powder inhaler market is worth US$ 18.9 Bn in 2021, and is set to expand 1.6X over the next ten years.

The dry powder inhaler market is expected to reach US$ 29.6 Bn by the end of 2031, with sales revenue expected to register 4.6% CAGR.

Utilization of physiologically-based pharmacokinetic models, development of advanced drug delivery systems, advanced inhaler device development and established guidelines on bioavailability/bioequivalence of inhaled products are some of the key trends being witnessed in this marketplace.

The U.S., Japan, China, U.K. and Germany are expected to drive demand for dry powder inhalers products.

North America is one of the key markets for dry powder inhalers, with the U.S. expected to account over 89.7% of the North American market during the forecast period.

Demand for dry powder inhalers in Europe is expected to register growth of 4.6% over the next ten years.

The U.S., China and Germany are key producers of dry powder inhalers products.

GlaxoSmithKline Plc, AstraZeneca Plc, Novartis AG, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A., Elpen S.A., Vectura Group Plc, Beximco Pharmaceuticals Ltd., Hovione, AptarGroup, Inc., Iconovo AB (Stevanato Group), Sava Healthcare Ltd., MannKind Corporation, Mylan N.V(a part of Viatris) and Pharmaxis are the key exporters of dry powder inhaler market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Road Map

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusion & Exclusion

3. Key Market Trends

    3.1. Key Trends Impacting The Market

    3.2. Innovation / Development Trends

4. Key Success Factors

    4.1. Key Regulations

    4.2. Product USPs and Features

    4.3. Strategic Promotional Activities

    4.4. Dry Powder Inhaler Product Adoption, By Region

5. Global Dry Powder Inhaler Market Demand (in Volume Units) Analysis 2016-2020 and Forecast, 2021-2031

    5.1. Historical Market Volume (Units) Analysis, 2016-2020

    5.2. Current and Future Market Volume (Units) Projections, 2021-2031

        5.2.1. Y-o-Y Growth Trend Analysis

6. Global Dry Powder Inhaler Market - Pricing Analysis

    6.1. Global Average Pricing Analysis Benchmark

    6.2. Regional Pricing Analysis, By Product

7. Global Dry Powder Inhaler Market Demand (in Value or Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031

    7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Market Background

    8.1. Macro-Economic Factors

        8.1.1. Global GDP Growth Outlook

        8.1.2. Global Healthcare Expenditure Outlook

        8.1.3. Growth of Healthcare Sector in Emerging nations

    8.2. Forecast Factors - Relevance & Impact

        8.2.1. Product Adoption Rate

        8.2.2. Innovative Product Launches

        8.2.3. Incidence of Chronic Respiratory Diseases

        8.2.4. Digital Technology Integration

        8.2.5. Cost of Device

        8.2.6. Regulatory Scenario

    8.3. Market Dynamics

        8.3.1. Drivers

        8.3.2. Restraints

        8.3.3. Opportunity Analysis

9. COVID19 Crisis Analysis

    9.1. Current COVID19 Statistics and Probable Future Impact

    9.2. Current GDP Projection and Probable Impact

    9.3. COVID19 and Impact Analysis

        9.3.1. By Product

        9.3.2. By Indication

        9.3.3. By Function

        9.3.4. By End User

        9.3.5. By Country

10. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Product 

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis by Product, 2016-2020

    10.3. Current and Future Market Size (US$ Mn) and Forecast by Product, 2021-2031

        10.3.1. Single Dose Dry Powder Inhalers

        10.3.2. Multi Dose Dry Powder Inhalers

    10.4. Market Attractiveness Analysis by Product 

11. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Indication

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis by Usage, 2016-2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Indication, 2021-2031

        11.3.1. Asthma

        11.3.2. Chronic Obstructive Pulmonary Disease (COPD)

        11.3.3. Pulmonary Arterial Hypertension

        11.3.4. Diabetes

        11.3.5. Cystic Fibrosis

    11.4. Market Attractiveness Analysis by Indication

12. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Function 

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis by Function, 2016-2020

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Function, 2021-2031

        12.3.1. Manually Operated Inhaler Devices

        12.3.2. Digitally Operated Inhaler Devices

    12.4. Market Attractiveness Analysis by Function

13. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by End User

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Mn) Analysis by End User, 2016-2020

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2021-2031

        13.3.1. Institutional Sales

            13.3.1.1. Hospital Pharmacies

            13.3.1.2. Cancer Research

            13.3.1.3. Office based Speciality Clinics

        13.3.2. Retail Sales

            13.3.2.1. Retail Pharmacies

            13.3.2.2. Drug Stores

        13.3.3. Mail Order Pharmacies

    13.4. Market Attractiveness Analysis by End User

14. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis by Region, 2016-2020

    14.3. Current Market Size (US$ Mn) Analysis and Forecast by Region, 2021-2031

        14.3.1. North America

        14.3.2. Latin America

        14.3.3. Europe

        14.3.4. Middle East and Africa (MEA)

        14.3.5. South Asia

        14.3.6. East Asia

        14.3.7. Oceania

    14.4. Market Attractiveness Analysis by Region

15. North America Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    15.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        15.3.1. By Country

            15.3.1.1. U.S.

            15.3.1.2. Canada

        15.3.2. By Product

        15.3.3. By Indication

        15.3.4. By Function

        15.3.5. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Product

        15.4.3. By Indication

        15.4.4. By Function

        15.4.5. By End User

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Latin America Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    16.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        16.3.1. By Country

            16.3.1.1. Brazil

            16.3.1.2. Mexico

            16.3.1.3. Argentina

            16.3.1.4. Rest of Latin America

        16.3.2. By Product

        16.3.3. By Indication

        16.3.4. By Function

        16.3.5. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Product

        16.4.3. By Indication

        16.4.4. By Function

        16.4.5. By End User

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Europe Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    17.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        17.3.1. By Country

            17.3.1.1. Germany

            17.3.1.2. Italy

            17.3.1.3. France

            17.3.1.4. U.K.

            17.3.1.5. Spain

            17.3.1.6. BENELUX

            17.3.1.7. Russia

            17.3.1.8. Rest of Europe

        17.3.2. By Product

        17.3.3. By Indication

        17.3.4. By Function

        17.3.5. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Product

        17.4.3. By Indication

        17.4.4. By Function

        17.4.5. By End User

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. South Asia Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    18.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        18.3.1. By Country

            18.3.1.1. India

            18.3.1.2. Thailand

            18.3.1.3. Indonesia

            18.3.1.4. Malaysia

            18.3.1.5. Rest of South Asia

        18.3.2. By Product

        18.3.3. By Indication

        18.3.4. By Function

        18.3.5. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Product

        18.4.3. By Indication

        18.4.4. By Function

        18.4.5. By End User

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. East Asia Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031

    19.1. Introduction

    19.2. Pricing Analysis

    19.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    19.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        19.4.1. By Country

            19.4.1.1. China

            19.4.1.2. Japan

            19.4.1.3. South Korea

        19.4.2. By Product

        19.4.3. By Indication

        19.4.4. By Function

        19.4.5. By End User

    19.5. Market Attractiveness Analysis

        19.5.1. By Country

        19.5.2. By Product

        19.5.3. By Indication

        19.5.4. By Function

        19.5.5. By End User

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

20. Oceania Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    20.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        20.3.1. By Country

            20.3.1.1. Australia

            20.3.1.2. New Zealand

        20.3.2. By Product

        20.3.3. By Indication

        20.3.4. By Function

        20.3.5. By End User

    20.4. Market Attractiveness Analysis

        20.4.1. By Country

        20.4.2. By Product

        20.4.3. By Indication

        20.4.4. By Function

        20.4.5. By End User

    20.5. Key Market Participants - Intensity Mapping

    20.6. Drivers and Restraints - Impact Analysis

21. Middle East and Africa Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031

    21.1. Introduction

    21.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020

    21.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031

        21.3.1. By Country

            21.3.1.1. GCC Countries

            21.3.1.2. South Africa

            21.3.1.3. Rest of Middle East and Africa

        21.3.2. By Product

        21.3.3. By Indication

        21.3.4. By Function

        21.3.5. By End User

    21.4. Market Attractiveness Analysis

        21.4.1. By Country

        21.4.2. By Product

        21.4.3. By Indication

        21.4.4. By Function

        21.4.5. By End User

    21.5. Key Market Participants - Intensity Mapping

    21.6. Drivers and Restraints - Impact Analysis

22. Country Level Dry Powder Inhaler Market Analysis 2021 & 2031 

    22.1. Introduction

        22.1.1. Market Value Proportion Analysis

        22.1.2. Global VS. Country Growth Comparison

    22.2. U.S. Dry Powder Inhaler Market Analysis

        22.2.1. By Product

        22.2.2. By Indication

        22.2.3. By Function

        22.2.4. By End User

    22.3. Canada Dry Powder Inhaler Market Analysis

        22.3.1. By Product

        22.3.2. By Indication

        22.3.3. By Function

        22.3.4. By End User

    22.4. Brazil Dry Powder Inhaler Market Analysis

        22.4.1. By Product

        22.4.2. By Indication

        22.4.3. By Function

        22.4.4. By End User

    22.5. Mexico Dry Powder Inhaler Market Analysis

        22.5.1. By Product

        22.5.2. By Indication

        22.5.3. By Function

        22.5.4. By End User

    22.6. Argentina Dry Powder Inhaler Market Analysis

        22.6.1. By Product

        22.6.2. By Indication

        22.6.3. By Function

        22.6.4. By End User 

    22.7. U.K. Dry Powder Inhaler Market Analysis

        22.7.1. By Product

        22.7.2. By Indication

        22.7.3. By Function

        22.7.4. By End User

    22.8. Germany Dry Powder Inhaler Market Analysis

        22.8.1. By Product

        22.8.2. By Indication

        22.8.3. By Function

        22.8.4. By End User

    22.9. France Dry Powder Inhaler Market Analysis

        22.9.1. By Product

        22.9.2. By Indication

        22.9.3. By Function

        22.9.4. By End User

    22.10. Spain. Dry Powder Inhaler Market Analysis

        22.10.1. By Product

        22.10.2. By Indication

        22.10.3. By Function

        22.10.4. By End User

    22.11. Italy Dry Powder Inhaler Market Analysis

        22.11.1. By Product

        22.11.2. By Indication

        22.11.3. By Function

        22.11.4. By End User

    22.12. Russia Dry Powder Inhaler Market Analysis

        22.12.1. By Product

        22.12.2. By Indication

        22.12.3. By Function

        22.12.4. By End User

    22.13. BENELUX Dry Powder Inhaler Market Analysis

        22.13.1. By Product

        22.13.2. By Indication

        22.13.3. By Function

        22.13.4. By End User

    22.14. China Dry Powder Inhaler Market Analysis

        22.14.1. By Product

        22.14.2. By Indication

        22.14.3. By Function

        22.14.4. By End User

    22.15. Japan Dry Powder Inhaler Market Analysis

        22.15.1. By Product

        22.15.2. By Indication

        22.15.3. By Function

        22.15.4. By End User

    22.16. South Korea Dry Powder Inhaler Market Analysis

        22.16.1. By Product

        22.16.2. By Indication

        22.16.3. By Function

        22.16.4. By End User

    22.17. India Dry Powder Inhaler Market Analysis

        22.17.1. By Product

        22.17.2. By Indication

        22.17.3. By Function

        22.17.4. By End User

    22.18. Thailand Dry Powder Inhaler Market Analysis

        22.18.1. By Product

        22.18.2. By Indication

        22.18.3. By Function

        22.18.4. By End User

    22.19. Indonesia Dry Powder Inhaler Market Analysis

        22.19.1. By Product

        22.19.2. By Indication

        22.19.3. By Function

        22.19.4. By End User

    22.20. Malaysia Dry Powder Inhaler Market Analysis

        22.20.1. By Product

        22.20.2. By Indication

        22.20.3. By Function

        22.20.4. By End User

    22.21. Australia Dry Powder Inhaler Market Analysis

        22.21.1. By Product

        22.21.2. By Indication

        22.21.3. By Function

        22.21.4. By End User

    22.22. New Zealand Dry Powder Inhaler Market Analysis

        22.22.1. By Product

        22.22.2. By Indication

        22.22.3. By Function

        22.22.4. By End User

    22.23. GCC Countries Dry Powder Inhaler Market Analysis

        22.23.1. By Product

        22.23.2. By Indication

        22.23.3. By Function

        22.23.4. By End User

    22.24. South Africa Dry Powder Inhaler Market Analysis

        22.24.1. By Product

        22.24.2. By Indication

        22.24.3. By Function

        22.24.4. By End User

23. Market Structure Analysis

    23.1. Market Analysis by Tier of Companies 

    23.2. Market Share Analysis of Top Players

    23.3. Market Presence Analysis

        23.3.1. By Regional Footprint of Players

        23.3.2. Product Footprint by Players

        23.3.3. Channel Footprint by Players

24. Competition Analysis

    24.1. Competition Dashboard

    24.2. Competition Benchmarking

    24.3. Competition Deep Dive 

        24.3.1. GlaxoSmithKline Plc

            24.3.1.1. Overview & Key Financials

            24.3.1.2. Product Portfolio

            24.3.1.3. Sales Footprint

            24.3.1.4. Analyst commentary

            24.3.1.5. Strategy

                24.3.1.5.1. Marketing Strategy

                24.3.1.5.2. Product Strategy

                24.3.1.5.3. Channel Strategy

        24.3.2. AstraZeneca Plc

            24.3.2.1. Overview & Key Financials

            24.3.2.2. Product Portfolio

            24.3.2.3. Sales Footprint

            24.3.2.4. Analyst commentary

            24.3.2.5. Strategy

                24.3.2.5.1. Marketing Strategy

                24.3.2.5.2. Product Strategy

                24.3.2.5.3. Channel Strategy

        24.3.3. Novartis AG

            24.3.3.1. Overview & Key Financials

            24.3.3.2. Product Portfolio

            24.3.3.3. Sales Footprint

            24.3.3.4. Analyst commentary

            24.3.3.5. Strategy

                24.3.3.5.1. Marketing Strategy

                24.3.3.5.2. Product Strategy

                24.3.3.5.3. Channel Strategy

        24.3.4. Teva Pharmaceutical Industries Limited

            24.3.4.1. Overview & Key Financials

            24.3.4.2. Product Portfolio

            24.3.4.3. Sales Footprint

            24.3.4.4. Analyst commentary

            24.3.4.5. Strategy

                24.3.4.5.1. Marketing Strategy

                24.3.4.5.2. Product Strategy

                24.3.4.5.3. Channel Strategy

        24.3.5. Boehringer Ingelheim GmbH

            24.3.5.1. Overview & Key Financials

            24.3.5.2. Product Portfolio

            24.3.5.3. Sales Footprint

            24.3.5.4. Analyst commentary

            24.3.5.5. Strategy

                24.3.5.5.1. Marketing Strategy

                24.3.5.5.2. Product Strategy

                24.3.5.5.3. Channel Strategy

        24.3.6. Cipla Limited

            24.3.6.1. Overview & Key Financials

            24.3.6.2. Product Portfolio

            24.3.6.3. Sales Footprint

            24.3.6.4. Analyst commentary

            24.3.6.5. Strategy

                24.3.6.5.1. Marketing Strategy

                24.3.6.5.2. Product Strategy

                24.3.6.5.3. Channel Strategy

        24.3.7. Chiesi Farmaceutici S.p.A.

            24.3.7.1. Overview & Key Financials

            24.3.7.2. Product Portfolio

            24.3.7.3. Sales Footprint

            24.3.7.4. Analyst commentary

            24.3.7.5. Strategy

                24.3.7.5.1. Marketing Strategy

                24.3.7.5.2. Product Strategy

                24.3.7.5.3. Channel Strategy

        24.3.8. Elpen S.A.

            24.3.8.1. Overview & Key Financials

            24.3.8.2. Product Portfolio

            24.3.8.3. Sales Footprint

            24.3.8.4. Analyst commentary

            24.3.8.5. Strategy

                24.3.8.5.1. Marketing Strategy

                24.3.8.5.2. Product Strategy

                24.3.8.5.3. Channel Strategy

        24.3.9. Vectura Group Plc

            24.3.9.1. Overview & Key Financials

            24.3.9.2. Product Portfolio

            24.3.9.3. Sales Footprint

            24.3.9.4. Analyst commentary

            24.3.9.5. Strategy

                24.3.9.5.1. Marketing Strategy

                24.3.9.5.2. Product Strategy

                24.3.9.5.3. Channel Strategy

        24.3.10. Beximco Pharmaceuticals Ltd.

            24.3.10.1. Overview & Key Financials

            24.3.10.2. Product Portfolio

            24.3.10.3. Sales Footprint

            24.3.10.4. Analyst commentary

            24.3.10.5. Strategy

                24.3.10.5.1. Marketing Strategy

                24.3.10.5.2. Product Strategy

                24.3.10.5.3. Channel Strategy

        24.3.11. Hovione

            24.3.11.1. Overview & Key Financials

            24.3.11.2. Product Portfolio

            24.3.11.3. Sales Footprint

            24.3.11.4. Analyst commentary

            24.3.11.5. Strategy

                24.3.11.5.1. Marketing Strategy

                24.3.11.5.2. Product Strategy

                24.3.11.5.3. Channel Strategy

        24.3.12. AptarGroup, Inc.

            24.3.12.1. Overview & Key Financials

            24.3.12.2. Product Portfolio

            24.3.12.3. Sales Footprint

            24.3.12.4. Analyst commentary

            24.3.12.5. Strategy

                24.3.12.5.1. Marketing Strategy

                24.3.12.5.2. Product Strategy

                24.3.12.5.3. Channel Strategy

        24.3.13. Iconovo AB (Stevanato Group)

            24.3.13.1. Overview & Key Financials

            24.3.13.2. Product Portfolio

            24.3.13.3. Sales Footprint

            24.3.13.4. Analyst commentary

            24.3.13.5. Strategy

                24.3.13.5.1. Marketing Strategy

                24.3.13.5.2. Product Strategy

                24.3.13.5.3. Channel Strategy

        24.3.14. Sava Healthcare Ltd.

            24.3.14.1. Overview & Key Financials

            24.3.14.2. Product Portfolio

            24.3.14.3. Sales Footprint

            24.3.14.4. Analyst commentary

            24.3.14.5. Strategy

                24.3.14.5.1. Marketing Strategy

                24.3.14.5.2. Product Strategy

                24.3.14.5.3. Channel Strategy

        24.3.15. MannKind Corporation

            24.3.15.1. Overview & Key Financials

            24.3.15.2. Product Portfolio

            24.3.15.3. Sales Footprint

            24.3.15.4. Analyst commentary

            24.3.15.5. Strategy

                24.3.15.5.1. Marketing Strategy

                24.3.15.5.2. Product Strategy

                24.3.15.5.3. Channel Strategy

        24.3.16. Mylan N.V(a part of Viatris)

            24.3.16.1. Overview & Key Financials

            24.3.16.2. Product Portfolio

            24.3.16.3. Sales Footprint

            24.3.16.4. Analyst commentary

            24.3.16.5. Strategy

                24.3.16.5.1. Marketing Strategy

                24.3.16.5.2. Product Strategy

                24.3.16.5.3. Channel Strategy

        24.3.17. Pharmaxis

            24.3.17.1. Overview & Key Financials

            24.3.17.2. Product Portfolio

            24.3.17.3. Sales Footprint

            24.3.17.4. Analyst commentary

            24.3.17.5. Strategy

                24.3.17.5.1. Marketing Strategy

                24.3.17.5.2. Product Strategy

                24.3.17.5.3. Channel Strategy

25. Assumptions and Acronyms Used

26. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 02: Global Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 03: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 04: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 05: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 06: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Region

Table 07: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 08: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 09: North America Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 10: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 11: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 12: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 13: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 14: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 15: Latin America Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 16: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 17: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 18: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 19: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 20: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 21: Europe Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 22: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 23: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 24: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 25: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 26: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 27: South Asia Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 28: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 29: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 30: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 31: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 32: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 33: East Asia Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 34: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 35: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 36: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 37: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 38: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 39: Oceania Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 40: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 41: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 42: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Table 43: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country

Table 44: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 45: MEA Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product

Table 46: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication

Table 47: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function

Table 48: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 02: Global Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 03: Global Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 04: Global Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 05: Global Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 06: Global Dry Powder Inhaler Market Volume ('000) Analysis, 2016-2020

Figure 07: Global Dry Powder Inhaler Market Volume ('000) & Y-o-Y Growth (%), 2021–2031

Figure 08: Global Average Pricing Analysis Benchmark USD (Unit) (2020)

Figure 09: Global Dry Powder Inhaler (Product: Single Dose Dry Powder Inhalers and Multi Dose Dry Powder Inhalers), Price Difference (US$) By Region, 2020

Figure 10: Global Dry Powder Inhaler (Product: Single Dose Dry Powder Inhalers and Multi Dose Dry Powder Inhalers), Price Difference (US$) By Region, 2031

Figure 11: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 12: Global Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2021–2031

Figure 13: Global Dry Powder Inhaler Market Absolute $ Opportunity Analysis, 2021-2031

Figure 14: Global Dry Powder Inhaler Market Share Analysis (%) by Product, 2021 & 2031

Figure 15: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Product, 2020–2031

Figure 16: Global Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 17: Global Dry Powder Inhaler Market Share Analysis (%) by Indication, 2021 & 2031

Figure 18: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Indication, 2020–2031

Figure 19: Global Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 20: Global Dry Powder Inhaler Market Share Analysis (%) by Function, 2021 & 2031

Figure 21: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Function, 2020–2031

Figure 22: Global Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 23: Global Dry Powder Inhaler Market Share Analysis (%) by End User, 2021 & 2031

Figure 24: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by End User, 2020–2031

Figure 25: Global Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 26: Global Dry Powder Inhaler Market Share Analysis (%) by Region, 2021 & 2031

Figure 27: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Region, 2020–2031

Figure 28: Global Dry Powder Inhaler Market Attractiveness Analysis by Region, 2021–2031

Figure 29: North America Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 30: North America Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 31: North America Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 32: North America Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 33: North America Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 34: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 35: North America Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 36: North America Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 37: North America Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 38: North America Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 39: North America Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 40: North America Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 41: Latin America Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 42: Latin America Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 43: Latin America Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 44: Latin America Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 45: Latin America Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 46: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 47: Latin America Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 48: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 49: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 50: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 51: Latin America Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 52: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 53: Europe Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 54: Europe Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 55: Europe Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 56: Europe Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 57: Europe Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 58: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 59: Europe Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 60: Europe Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 61: Europe Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 62: Europe Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 63: Europe Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 64: Europe Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 65: South Asia Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 66: South Asia Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 67: South Asia Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 68: South Asia Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 69: South Asia Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 70: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 71: South Asia Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 72: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 73: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 74: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 75: South Asia Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 76: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 77: East Asia Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 78: East Asia Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 79: East Asia Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 80: East Asia Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 81: East Asia Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 82: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 83: East Asia Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 84: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 85: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 86: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 87: East Asia Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 88: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 89: Oceania Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 90: Oceania Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 91: Oceania Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 92: Oceania Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 93: Oceania Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 94: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 95: Oceania Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 96: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 97: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 98: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 99: Oceania Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 100: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 101: MEA Dry Powder Inhaler Market Share, By Product, 2021 (E)

Figure 102: MEA Dry Powder Inhaler Market Share, By Indication, 2021 (E)

Figure 103: MEA Dry Powder Inhaler Market Share, By Function, 2021 (E)

Figure 104: MEA Dry Powder Inhaler Market Share, By End User, 2021 (E)

Figure 105: MEA Dry Powder Inhaler Market Share, By Region, 2021 (E)

Figure 106: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020

Figure 107: MEA Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031

Figure 108: MEA Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031

Figure 109: MEA Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031

Figure 110: MEA Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031

Figure 111: MEA Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031

Figure 112: MEA Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031

Figure 113: U.S. Market Value Proportion Analysis, 2021

Figure 114: Global Vs. U.S. Growth Comparison

Figure 115: U.S. Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 116: U.S. Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 117: U.S. Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 118: U.S. Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 119: Canada Market Value Proportion Analysis, 2021

Figure 120: Global Vs. Canada Growth Comparison

Figure 121: Canada Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 122: Canada Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 123: Canada Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 124: Canada Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 125: Brazil Market Value Proportion Analysis, 2021

Figure 126: Global Vs. Brazil Growth Comparison

Figure 127: Brazil Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 128: Brazil Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 129: Brazil Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 130: Brazil Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 131: Mexico Market Value Proportion Analysis, 2021

Figure 132: Global Vs. Mexico Growth Comparison

Figure 133: Mexico Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 134: Mexico Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 135: Mexico Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 136: Mexico Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 137: Argentina Market Value Proportion Analysis, 2021

Figure 138: Global Vs. Argentina Growth Comparison

Figure 139: Argentina Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 140: Argentina Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 141: Argentina Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 142: Argentina Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 143: U.K. Market Value Proportion Analysis, 2021

Figure 144: Global Vs. U.K. Growth Comparison

Figure 145: U.K. Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 146: U.K. Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 147: U.K. Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 148: U.K. Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 149: Germany Market Value Proportion Analysis, 2021

Figure 150: Global Vs. Germany Growth Comparison

Figure 151: Germany Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 152: Germany Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 153: Germany Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 154: Germany Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 155: France Market Value Proportion Analysis, 2021

Figure 156: Global Vs. France Growth Comparison

Figure 157: France Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 158: France Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 159: France Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 160: France Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 161: Spain Market Value Proportion Analysis, 2021

Figure 162: Global Vs. Spain Growth Comparison

Figure 163: Spain Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 164: Spain Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 165: Spain Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 166: Spain Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 167: Italy Market Value Proportion Analysis, 2021

Figure 168: Global Vs. Italy Growth Comparison

Figure 169: Italy Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 170: Italy Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 171: Italy Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 172: Italy Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 173: Russia Market Value Proportion Analysis, 2021

Figure 174: Global Vs. Russia Growth Comparison

Figure 175: Russia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 176: Russia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 177: Russia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 178: Russia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 179: BENELUX Market Value Proportion Analysis, 2021

Figure 180: Global Vs. BENELUX Growth Comparison

Figure 181: BENELUX Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 182: BENELUX Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 183: BENELUX Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 184: BENELUX Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 185: China Market Value Proportion Analysis, 2021

Figure 186: Global Vs. China Growth Comparison

Figure 187: China Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 188: China Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 189: China Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 190: China Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 191: Japan Market Value Proportion Analysis, 2021

Figure 192: Global Vs. Japan Growth Comparison

Figure 193: Japan Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 194: Japan Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 195: Japan Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 196: Japan Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 197: South Korea Market Value Proportion Analysis, 2021

Figure 198: Global Vs. South Korea Growth Comparison

Figure 199: South Korea Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 200: South Korea Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 201: South Korea Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 202: South Korea Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 203: India Market Value Proportion Analysis, 2021

Figure 204: Global Vs. India Growth Comparison

Figure 205: India Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 206: India Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 207: India Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 208: India Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 209: Thailand Market Value Proportion Analysis, 2021

Figure 210: Global Vs. Thailand Growth Comparison

Figure 211: Thailand Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 212: Thailand Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 213: Thailand Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 214: Thailand Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 215: Indonesia Market Value Proportion Analysis, 2021

Figure 216: Global Vs. Indonesia Growth Comparison

Figure 217: Indonesia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 218: Indonesia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 219: Indonesia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 220: Indonesia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 221: Malaysia Market Value Proportion Analysis, 2021

Figure 222: Global Vs. Malaysia Growth Comparison

Figure 223: Malaysia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 224: Malaysia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 225: Malaysia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 226: Malaysia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 227: Australia Market Value Proportion Analysis, 2021

Figure 228: Global Vs. Australia Growth Comparison

Figure 229: Australia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 230: Australia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 231: Australia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 232: Australia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 233: New Zealand Market Value Proportion Analysis, 2021

Figure 234: Global Vs. New Zealand Growth Comparison

Figure 235: New Zealand Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 236: New Zealand Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 237: New Zealand Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 238: New Zealand Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 239: GCC Countries Market Value Proportion Analysis, 2021

Figure 240: Global Vs. GCC Countries Growth Comparison

Figure 241: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 242: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 243: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 244: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Figure 245: South Africa Market Value Proportion Analysis, 2021

Figure 246: Global Vs. South Africa Growth Comparison

Figure 247: South Africa Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031

Figure 248: South Africa Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031

Figure 249: South Africa Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031

Figure 250: South Africa Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Respiratory Devices Market

Published : February 2021

Healthcare

Sleep Apnea Diagnostic Systems Market

Published : August 2021

Healthcare

Respiratory Inhaler Devices Market

Published : January 2021

Google translate

Dry Powder Inhaler Market